Lyrica
Product Images NDC 68258-7047

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Lyrica (NDC 68258-7047). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Ndc 68258-7047-xx (Ndc 68258 7047 Xx Pfizer)

Ndc 68258-7047-xx (Ndc 68258 7047 Xx Pfizer)
This is a description of a medicine that is a white hard-gelatin capsule containing 150 mg of pregabalin manufactured by Pfizer Pharmaceuticals LLC. The capsule has Pfizer printed on the cap and PGN 150 on the body. The bulk source National Drug Code (NDC) is 00071-1016-68. It is packaged in a tight/light-resistant container with a warning to keep out of children’s reach and caution not to transfer to any person other than the patient who was prescribed the medicine. The medicine should be stored at 77° F. It is recommended to avoid alcohol while taking the medicine as it may cause drowsiness.*
FDA Label Image

Figure (Lyrica 01)

Figure (Lyrica 01)
FDA Label Image

Chemical Structure (Lyrica 02)

Chemical Structure (Lyrica 02)
FDA Label Image

Figure 1 (Lyrica 03)

Figure 1 (Lyrica 03)
FDA Label Image

Figure 2 (Lyrica 04)

Figure 2 (Lyrica 04)
FDA Label Image

Figure 3 (Lyrica 05)

Figure 3 (Lyrica 05)
FDA Label Image

Figure 4 (Lyrica 06)

Figure 4 (Lyrica 06)
FDA Label Image

Figure 5 (Lyrica 07)

Figure 5 (Lyrica 07)
The text seems to be a chart or a table that displays the percentage of patients who have improved after taking different drugs. Two drugs seem to be mentioned, Pregatalin and Pregabalin, given in specific doses three times a day. Another term "Placata" is also present, but its context is not clear. The chart also displays percentages of improvement in pain from baseline, which could suggest that the drugs are pain medications. However, the text is not entirely readable, and it's not possible to extract more information from it.*
FDA Label Image

Figure 6 (Lyrica 08)

Figure 6 (Lyrica 08)
FDA Label Image

Figure 7 (Lyrica 09)

Figure 7 (Lyrica 09)
FDA Label Image

Figure 8 (Lyrica 10)

Figure 8 (Lyrica 10)
FDA Label Image

Figure 9 (Lyrica 11)

Figure 9 (Lyrica 11)
FDA Label Image

Figure 10 (Lyrica 12)

Figure 10 (Lyrica 12)
The text provides a table showing the percentage of subjects who improved from baseline to week 12 using Pregevalin and Placeso. However, there is not enough information to interpret the table or what is being improved. The text is not readable as it contains non-English characters such as "w0".*
FDA Label Image

Figure 11 (Lyrica 13)

Figure 11 (Lyrica 13)
This is a report showing the percentage of subjects who improved after taking Pregabalin and Placebo. The percentage of those who improved is 100% but there are additional data points which are not readable due to the text being in a graphic format.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.